A Delluc, E Pasquier, L de Saint Martin, D Mottier. Rituximab’s cost for the treatment of primary cold agglutinin disease should not limit its use. haematol [Internet]. 2006Mar.1 [cited 2024Apr.26];91(3):ECR05-ECR05. Available from: https://haematologica.org/article/view/3913